# R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma

> **NCT01278602** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 50 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** R-ESHAP

## Key facts

- **NCT ID:** NCT01278602
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2013-12
- **Final completion:** 2014-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01278602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01278602, "R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01278602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*